Enjay referenced a paper comparing Covid mechanism
Post# of 155530
(Total Views: 772)
Posted On: 03/02/2022 5:15:32 AM
Enjay referenced a paper comparing Covid mechanisms with those of other hyperinflammatory diseases. It was a nice find.
Two things struck me. First, there is a quotable line in the paper: "inhibition of the CCR5-CCL4 axis by Leronlima (anti-CCR5 monoclonal antibody)... [and others] have been shown to ameliorate, in some cases, severe COVID-19 manifestations."
I say quotable because this line directly refutes the FDA letter and the FDA warning, both of which claim that Leron has NO EFFICACY against Covid. Of course it does. But it might be useful, in replying to the FDA warning, to use these findings. Show the FDA this conclusion from a non-CYDY source!
The other thing that struck me was the Brazilian origins of the paper. It has no less than 17 Brazilian authors, including the first 16 named. Virtually all from Sao Paulo, where the Leron trial has the most sites.
I can't be sure there is a connection, but it would make sense for them to be using data about Leronlimab's ability to ameliorate "severe Covid-19 manifestations" from our Brazilian trial. And this, in return, would mean that not only have we been enrolling patients there, but Leronlimab has been working on Covid patients in Brazil.
The paper is dated Feb. 10th, revised Feb. 24th.
Given that we haven't had any information about the Brazil trial, it could be that this is a useful peek into what is going on down there.
Two things struck me. First, there is a quotable line in the paper: "inhibition of the CCR5-CCL4 axis by Leronlima (anti-CCR5 monoclonal antibody)... [and others] have been shown to ameliorate, in some cases, severe COVID-19 manifestations."
I say quotable because this line directly refutes the FDA letter and the FDA warning, both of which claim that Leron has NO EFFICACY against Covid. Of course it does. But it might be useful, in replying to the FDA warning, to use these findings. Show the FDA this conclusion from a non-CYDY source!
The other thing that struck me was the Brazilian origins of the paper. It has no less than 17 Brazilian authors, including the first 16 named. Virtually all from Sao Paulo, where the Leron trial has the most sites.
I can't be sure there is a connection, but it would make sense for them to be using data about Leronlimab's ability to ameliorate "severe Covid-19 manifestations" from our Brazilian trial. And this, in return, would mean that not only have we been enrolling patients there, but Leronlimab has been working on Covid patients in Brazil.
The paper is dated Feb. 10th, revised Feb. 24th.
Given that we haven't had any information about the Brazil trial, it could be that this is a useful peek into what is going on down there.
(14)
(0)